History of polymetastatic disease. Patients with genuine oligometastatic disease and 1-3 oligoprogressive lesions are only allowed if ablative therapy of all metastases is deemed impossible.
Under 1st to 2nd systemic treatment line with hormonotherapy and/or CDK4/6 inhibitors for at least 6 months before progression.
Progressive disease at 1-3 extracranial sites.
Ability to treat all progressive lesions locally according to the treating radiation oncologist.
You may not be if
Second malignancy if it is not in complete remission.
Previous local treatment for oligoprogression under the current systemic treatment line
Current progression in a lesion that has been treated with SBRT before and is not amendable for surgery or radiofrequency ablation (RFA).
Progressive or newly diagnosed brain metastases. Known brain metastases that have been nonprogressive for at least 6 months, are not an exclusion criterion.
Inability to continue the same ST line after local therapy (for example because of toxicity or patient refusal).
Pregnancy.
Inability to sign the informed consent.
Clareo Health | Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)
